johnson & johnson spravato - Search News

Depression, FDA and Spravato

Hosted on MSN · 6m

FDA Clears Spravato For Monotherapy Depression Treatments

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression,

UPI News on MSN · 1h

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

JnJ Spravato gets USFDA nod as monotherapy for adults with treatment-resistant depression

Titusville: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray,

1h

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone ...

17h

Johnson & Johnson announces FDA approves sNDA for Spravato

Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results